|
#
|
Title
|
Authors
|
Affiliations
|
Keywords
|
|
P107
|
CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against GBM
|
Catalina Soare1, Tanvir Ahmed1, Julie Joseph1, Anne-Catherine Fluckiger1, Barthelemy Ontsouka1, Abebaw Diress1, Jasminka Bozic1, Marc Kirchmeier1, Francisco Diaz-Mitoma1, David E Anderson1
|
1VBI Vaccines, Cambridge, MA, USA
|
Antigen presenting cells | Tumor antigens | T cell | Vaccine
|
|
P108
|
Induction of folate receptor alpha-specific Th17 T cell immunity in ovarian cancer patients
|
Matthew Block1, Kimberly Kalli1, Jacob Allred1, Courtney Erskine1, Allan Dietz1, Michael Gustafson1, Yi Lin1, Keith Knutson2, Martin Cannon3
|
1Mayo Clinic, Rochester, MN, USA 2Mayo Clinic, Jacksonville, FL, USA 3University of Arkansas for Medical Sciences, Little Rock, AR, USA
|
Vaccine | Dendritic cell | Immune monitoring | Tumor antigens | Antibody | T cell | Solid tumors | Cytokine | Clinical trial
|
|
P109
|
Anti-NY-ESO-1 Immune Response and Survival Benefit After LV305 Therapy in Patients With Advanced Sarcoma and Other Solid Tumors
|
Neeta Somaiah1, Matthew Block2, Joseph W. Kim3, Geoffrey Shapiro4, Khanh Tu Do4, Patrick Hwu1, Joseph Paul Eder3, Robin Lewis Jones5, Sacha Gnjatic6, Hailing Lu7, Jan H. ter Meulen7, Michael Chen9, Chet Bohac8, Frank Hsu8, Seth Pollack10
|
1MD Anderson Cancer Center, Houston, TX, USA 2Mayo Clinic, Rochester, MN, USA 3Yale University, New Haven, CT, USA 4Dana Farber Cancer Institute, Brookline, MA, USA 5Royal Marsden NHS, London, United Kingdom 6Tisch Cancer Institute, New York, CA, USA 7Immune Design, Seattle, WA, USA 8Immune Design, South San Francisco, CA, USA 9Biostatistics, South San Francisco, CA, USA 10Fred Hutchinson Cancer Research Center, Seattle, WA, USA
|
Dendritic cell | Biomarkers | Clinical trial | Vaccine | Solid tumors | Tumor antigens
|
|
P110
|
MEK inhibition augments Talimogene laherparepvec (T-VEC)-mediated in vitromelanoma oncolysis and induces in vivo tumor regression
|
Howard Kaufman1, Praveen Bommareddy1, Anne Silk1, Andrew Zloza1, Sachin Jhawar1
|
1Rutgers University, New Brunswick, NJ, USA
|
Tumor microenvironment | Vaccine | Solid tumors
|
|
P111
|
Initial Safety and Production Efficiency of an Autologous Tumor Lysate-Loaded Yeast Cell Wall Particle Vaccine
|
Tommy Brown1, Kaitlin Peace1, Myers John1, Timothy Vreeland2, Diane Hale1, Doreen Jackson1, Julia Green1, Jamie Berry3, Clifton Guy1, Herbert Garth1, Xianzhong Yu4, Thomas Wagner5, George Peoples6
|
1Brooke Army Medical Center, San Antonio, TX, USA 2University of Texas MD Anderson Cancer Center, Houston, TX, USA 3Womack Army Medical Center, Fort Bragg, NC, USA 4Clemson University, Clemson, SC, USA 5Orbis Health Solutions, Greenville, SC, USA 6Metis Foundation, San Antonio, TX, USA
|
Vaccine | Solid tumors | Dendritic cell | Tumor antigens | Targeted therapy | Clinical trial | Antigen presenting cells | T cell | Monocyte/Macrophage | Immune adjuvant
|
|
P112
|
Telomerase peptide vaccine treatment of patients with locally advanced or metastatic non-small cell lung cancer: Report from a phase I/IIA trial
|
Tormod Kyrre Guren1, Else Marit Inderberg2, Paal Fr. Brunsvig1, Odd Terje Brustugun3, Jon Amund Kyte1, Jens Bjørheim4, Wenche Rasch4, Claudius H. Reisse1, Gustav Gaudernack4, Steinar Aamdal1
|
1Oslo University Hospital, Oslo, Norway 2University of Oslo, Oslo, Norway 3Vestre Viken Hospital Trust, Drammen, Norway 4Ultimovacs AS, Oslo, Norway
|
Clinical trial | Vaccine | Immune monitoring | Clinical study | Solid tumors
|
|
P113
|
OncoPept VAC: A robust TCR binding algorithm to prioritize neoepitope using tumor mutation (DNAseq) and gene expression (RNAseq) data
|
Papia Chakraborty1, Amit Chaudhuri1, Vasumathi Kode1, Snigdha Majumdar1, Priyanka Shah1, Malini Manoharan1, Ravi Gupta1
|
1MedGenome Inc, Foster City, CA, USA
|
Neoantigens | Adoptive immunotherapy | T cell | Vaccine
|
|
P114
|
No toxicity and long-term survival up to 16-years from repeated oncolytic vaccine systemic immunotherapy in advanced melanoma: Teaching us lessons.
|
Brendon Coventry1, Carrie Lilly1, Tony Michele2, Peter Hersey3
|
1University of Adelaide, Adelaide, Australia 2Adelaide Oncology & Haematology, North Adelaide, South Australia, Australia 3University of Sydney, Sydney, Australia
|
Clinical study | Clinical trial | Immune toxicity | Vaccine | Solid tumors | Immune adjuvant
|
|
P115
|
Inflammatory Response After Immunotherapy with a Yeast-CEA Therapeutic Cancer Vaccine in Metastatic Medullary Thyroid Cancer
|
Jaydira Del Rivero1, Ann Gramza2, Myrna Rausckhorts1, Marijo Bilusic1, Fatima Karzai1, Julius Strauss1, Lisa Cordes1, William L. Dahut1, Jeffrey Schlom1, James L. Gulley1, Ravi A. Madan1
|
1National Cancer Institute/National Institutes of Health, Bethesda, MD, USA 2Medstar Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA
|
Inflammation | Tumor microenvironment | Vaccine | Clinical trial | Clinical study
|
|
P116
|
Heat-inactivated modified vaccinia virus Ankara (MVA) as vaccine adjuvant
|
Ning Yang1, Stewart Shuman1, Taha Merghoub1, Jedd Wolchok1, Liang Deng1
|
1Memorial Sloan Kettering Cancer Center, New York, NY, USA
|
Antigen presenting cells | Dendritic cell | Checkpoint blockade | Vaccine | T cell | Tumor antigens
|
|
P117
|
DNA-based cancer vaccines designed by SynCon® technology break tolerance in genetically diverse pre-clinical models
|
Bradley Garman1, Elizabeth K Duperret2, Bernadette Ferraro1, Jewell N Walters1, Kimberly A Kraynyak1, Emma Masteller1, Jian Yan1, Amir S Khan1, David B Weiner2, Laurent M Humeau1
|
1Inovio Pharmaceuticals, Inc., Plymouth Meeting, PA, USA 2The Wistar Institute, Philadelphia, PA, USA
|
Tumor antigens | T cell | Vaccine | Immune tolerance
|
|
P118
|
Gp96-Ig/Costimulator Combination Vaccine Improves T cell Priming, Enhances Immunity, Memory, and Tumor Elimination
|
Louis Gonzalez1, Louise Giffin1, Jason Rose1, George Fromm1, Suresh De Silva1, Taylor Schreiber1, Jeff Hutchins1
|
1Heat Biologics, Durham, NC, USA
|
T cell | Vaccine | Immune adjuvant
|
|
P119
|
Optimization of antigenic composition of a dendritic-cell targeting MIP3α-antigen vaccine and the efficacy of additional IL-10 neutralization therapy in the B16F10 mouse melanoma model.
|
James Gordy1, Richard Markham1
|
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
|
Dendritic cell | Tumor antigens | Vaccine | Chemokine | Inflammation | Tumor microenvironment
|
|
P120
|
Streamlining approaches for the selection of T cell neo-epitopes: from mutanome to therapeutic personalized cancer vaccine
|
Guilhem Richard1, Leonard Moise1,2, Matthew Ardito1, Frances Terry1, Gad Berdugo3, William Martin1, Anne De Groot1,2
|
1EpiVax Inc., Providence, RI, USA 2University of Rhode Island, Providence, RI, USA 3EpiVax Oncology LLC, Providence, RI, USA
|
Vaccine | Regulatory T cell (Treg) | Bioinformatics | Immune tolerance | Neoantigens | Systems biology | T cell | Tumor antigens
|
|
P121
|
Phase 1 dose escalation trial of CV301
|
Julius Strauss1, Jaydira Del Rivero1, Ravi A. Madan1, Jennifer Marte1, Alanvin Orpia2, Eva Wagner3, Cesar Pico Navarro4, Christopher Heery4, Jeffrey Schlom1, James Gulley1
|
1Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA 2Leidos Biomedical Research, Inc., Bethesda, MD, USA 3Bavarian Nordic, Martinsried, Germany 4Bavarian Nordic, Morrisville, NC, USA
|
Vaccine | Tumor antigens | Costimulation | Dendritic cell | Clinical study | T cell | Clinical trial | Immune tolerance | Solid tumors | Immune contexture
|
|
P122
|
N-terminally extended proline residues influences the HLA class I antigen processing and decreases CTL responses.
|
Ayumi Hongo1, Takayuki Kanaseki1, Serina Tokita1, Vitaly Kochin1, Toshihiko Torigoe1
|
1Sapporo Medical University, Sapporo, Japan
|
Antigen presenting cells | Targeted therapy | Tumor antigens | T cell | Immune contexture | Neoantigens | Vaccine
|
|
P123
|
A novel oncolytic virus expressing multiple immune regulatory factors to change tumor immune microenvironment and to cause lasting complete tumor eradication in animal models
|
WILLIAM JIA1, JUN Ding2, Erica Lee2, Dmitry Chouljenko2, Guoyu Liu2, Yanal Murad2, Will Liu2, Zahid Delwar1, Xuexian Bu1
|
1University of British Columbia, Vancouver, BC, Canada 2Virogin Biotech Ltd, Vancouver, BC, Canada
|
Tumor microenvironment | Cytokine
|
|
P124
|
In vitro mode of action of ilixadencel - a cell-based allogeneic immune primer for intratumoral administration
|
Grammatiki Fotaki1, Chuan Jin1, Di Yu1, Magnus Essand1, Alex Karlsson-Parra1
|
1Institution of Immunologi, Genetics and Pathology, 751 85 Uppsala, Sweden
|
Neoantigens | Chemokine | Cytokine | Immune adjuvant | NK/NK T cell | Solid tumors | Vaccine | Dendritic cell | Tumor microenvironment
|
|
P125
|
Immunogenicity of Human Papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCCa)
|
Charu Aggarwal1, Roger Cohen1, Matthew Morrow2, Kimberly Kraynyak2, Dawson Knoblock2, Joshua Bauml1, Gregory Weinstein1, Jian Yan2, Jean Boyer3, Drishty Mangrolia2, Sandra Oyola2, Susan Duff2, David Weiner4, Ildiko Csiki2, Mark Bagarazzi2
|
1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA 2Inovio Pharmaceuticals, Plymouth Meeting, PA, USA 3Inovio Pharmaceuticals, San Diego, CA, USA 4Wistar Institute, Philadelphia, PA, USA
|
Immune tolerance | Checkpoint blockade | Immune suppression | T cell | Tumor evasion | Vaccine | Clinical trial
|
|
P126
|
Cancer immunotherapy with novel vaccine nanodiscs for efficient elimination of mucosal tumors
|
Rui Kuai1, Yao Xu1, Anna Schwendeman1, James Moon1
|
1University of Michigan, Ann Arbor, MI, USA
|
Vaccine | Tumor infiltrating lymphocytes (TILs) | Tumor antigens | Antigen presenting cells | Dendritic cell | Tumor microenvironment
|
|
P127
|
Transduction of MAGE-A1, A3, A4, A10 and IL-12 by ZVex®, a dendritic cell targeting platform induces robust multi-antigen T-cell immune responses without antigenic interference or immunodominance
|
Tina C. Albershardt1, Anshika Bajaj1, Jardin Leleux1, Tsai-Yu Lin1, Rebecca S. Reeves1, Lisa Y. Ngo1, Ryan White1, Jordan E. Krull1, Reice D. James1, Jan ter Meulen1, Peter Berglund1
|
1Immune Design, Seattle, WA, USA
|
Antigen presenting cells | Dendritic cell | Cytokine | Tumor antigens | T cell | Vaccine
|
|
P128
|
PD-L1-specific T cells can be activated by interferon-y and have an anti-tumor effect
|
Mia Thorup Lundsager1, Mads Hald Andersen2
|
1Center for Cancer Immune Therapy, Herlev Hospital, Denmark 1IO Biotech ApS, Copenhagen, Denmark, 2Center for Cancer Immune Therapy, Herlev Hospital, Denmark,2IO Biotech ApS, Copenhagen, Denmark
|
Tumor antigens | Vaccine | T cell
|
|
P129
|
Distinct patterns of clonotypic T cell responses in metastatic castration-resistant prostate cancer pts treated with standard sipuleucel-T (sip-T) compared with pts receiving a booster treatment
|
Li Zhang1, Harini Kandadi2, Alan Paciorek1, Tao He3, Nadeem Sheikh2, Lawrence Fong1
|
1University of California San Francisco, San Francisco, CA, USA 2Dendreon Pharmaceuticals Inc., Seattle, WA, USA 3College of Science and Engineering, San Francisco State University, San Francisco, CA, USA
|
T cell | Vaccine | Solid tumors
|
|
P130
|
In situ vaccination with Flt3L, radiation, and poly-ICLC induces a potent immune response in patients with follicular lymphoma.
|
Thomas Marron1, Linda Hammerich1, Miriam Merad1, Adeeb Rahman1, Tibor Keler2, Thomas Davis2, Andres Salazar3, Nina Bhardwaj1, Joshua Brody1
|
1Icahn School of Medicine at Mount Sinai, New York, NY, USA 2Celldex Inc, Hampton, NJ, USA 3Oncovir, Inc, Washington, DC, USA
|
Dendritic cell | TLR | Tumor microenvironment | Immune monitoring | Clinical study | Biomarkers | Checkpoint blockade | Radiotherapy | Tumor infiltrating lymphocytes (TILs) | Vaccine
|
|
P131
|
Contrasting roles of cyclooxygenase-1 and cyclooxygenase-2 in cell-mediated immunity to Listeria monocytogenes
|
Courtney McDougal1, Erin Theisen1, John-Demian Sauer1
|
1University of Wisconsin - Madison, Madison, WI, USA
|
T cell | Antigen presenting cells | Inflammation | Monocyte/Macrophage | Dendritic cell | Vaccine
|
|
P132
|
Overexpression of androgen receptor (AR) in prostate cancer cells following androgen deprivation increases recognition by AR-specific CD8+ T cells
|
Melissa Gamat1, Brian Olson1, Joseph Seliski1, Thomas Sawicki1, Justin Jeffery1, Leigh Ellis2, Charles Drake3, Jamey Weichert1, Douglas McNeel1
|
1University of Wisconsin, Madison, WI, USA 2Dana Farber Cancer Institute, Boston, MA, USA 3Columbia University, New York, NY, USA
|
Tumor antigens | T cell | Vaccine
|
|
P133
|
A heterologous prime-boost vaccination strategy combining a Listeria and DNA-based vaccine encoding prostatic acid phosphatase (PAP) elicits a strong antigen-specific, anti-tumor response
|
Laura Johnson1, Dirk Brockstedt2, Bill Hanson2, Meredith Leong2, Peter Lauer2, Douglas McNeel1
|
1University of Wisconsin, Madison, WI, USA 2Aduro Biotech, Berkeley, CA, USA
|
Tumor antigens | Vaccine
|
|
P134
|
Preclinical in vivo model validation for the development of a novel vaccine based strategy targeting IDO1
|
Souvik Dey1, Erika Sutanto-Ward1, Arpita Mondal1, Katharina Luise Maria Kopp2, Mai-Britt Zocca2, Ayako Wakatsuki Pedersen2, Mads Hald Andersen3, Alexander J. Muller1
|
1Lankenau Institute for Medical Research, Wynnewood, PA, USA 2IO Biotech ApS, Copenhagen, Denmark 3University of Copenhagen, Copenhagen, Denmark
|
Immune tolerance | Inflammation | Tumor evasion | Vaccine | T cell | Immune suppression | Tumor antigens | Tumor microenvironment | Metabolism | Checkpoint blockade
|
|
P135
|
PEGylated tumor membrane nano-vesicles for eliciting adaptive immune responses against melanoma
|
Lukasz Ochyl1, James Moon1
|
1University of Michigan, Ann Arbor, MI, USA
|
Immune adjuvant | TLR | Tumor antigens | T cell | Vaccine
|
|
P136
|
Dendritic cell vaccination combined with chemotherapy for advanced or relapsed head and neck cancer patients induces immunological and clinical responses
|
Shuichi Ota1
|
1Sapporo Hokuyu Hospital, Sapporo, Japan
|
Dendritic cell | TLR | Clinical study | MDSC | Vaccine | Antigen presenting cells | Clinical trial | Solid tumors
|
|
P137
|
Immune mechanisms of the response to TG4010, a viral-based vaccine, in patients with advanced non-small cell lung carcinoma
|
Kaidre Bendjama1, Eric Quemeneur1, Bérangère Bastien1, Maud Brandely-Talbot1
|
1Transgene S.A., Illkirch-Graffenstaden, France
|
Biomarkers | Clinical study | Immune monitoring | Immune contexture | T cell | Tumor antigens | Vaccine
|
|
P138
|
Tumor-specific CD8 T cell checkpoint expressions in melanoma patients that received adenovirally-engineered DC vaccine +/- IFN-α
|
Patricia M Santos1, Lisa H Butterfield1, Samuel Du1, John M Kirkwood1
|
1University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA
|
Antigen presenting cells | Dendritic cell | Clinical trial | Tumor antigens | Checkpoint blockade | Immune monitoring | Vaccine | T cell
|
|
P139
|
A viral vectored vaccine based on shared tumor neoantigens for prevention and treatment of MicroSatellite Instable (MSI) cancers
|
Guido Leoni1, Anna Morena D'Alise1, Gabriella Cotugno1, Federica Mori1, Maria Teresa Catanese1, Francesca Langone1, Imma Fichera1, Maria De Lucia2, Rosa Vitale1, Adriano Leuzzi1, Elena Di Matteo1, Antonella Folgori1, Stefano Colloca1, Alfredo Nicosia1,2, Armin Lahm1, Elisa Scarselli1
|
1Nouscom srl, Rome, Italy 2University of Naples Federico II, Naples, Italy
|
Bioinformatics | Neoantigens | Tumor antigens | Vaccine
|
|
P140
|
NKTR-214 enhances anti-tumor T cell immune responses induced by checkpoint blockade or vaccination
|
Meenu Sharma1, Faisal Fa’ak1, Louise Janssen1, Hiep Khong1, Zhilan Xiao1, Yared Hailemichael1, Manisha Singh1, Christina Vianden1, Adi Diab1, Jonathan Zalevsky2, Ute Hoch2, Willem Overwijk1
|
1UT MD Anderson Cancer Center, Houston, TX, USA 2Nektar Therapeutics, San Francisco, CA, USA
|
Checkpoint blockade | Vaccine | T cell
|
|
P141
|
A Multi-center Study of hTERT Immunotherapy in Adults with Solid Tumors at High Risk of Relapse Post-standard Therapy
|
Anthony F. Shields1, Autumn J. McRee2, Jennifer M. Johnson3, Weijing Sun4, Ashish Chintakuntlawar5, Albert J. Sylvester6, Naseem Prostak6, Kimberly A. Kraynyak6, Matthew P. Morrow6, Jeffrey M. Skolnik6, Robert H. Vonderheide7
|
1Karmanos Cancer Institute, Detroit, MI, USA 2University of North Carolina, Chapel Hill, NC, USA 3Thomas Jefferson University, Philadelphia, PA, USA 4University of Pittsburgh, Pittsburgh, PA, USA 5Mayo Clinic, Rochester, MN, USA 6Inovio Pharmaceuticals, Plymouth Meeting, PA, USA 7Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
|
Clinical study | Tumor antigens | Clinical trial | Vaccine | Solid tumors
|
|
P142
|
In situ immunocytokine vaccination, radiation and checkpoint blockade therapy prevents engraftment of brain metastases in a murine melanoma model
|
Raghava Sriramaneni1, Paul A. Clark1, Clinton Heinze1, Emily I. Guy1, Jasdeep Kler2, Sara Busche3, Jonathan A. Lubin2, Peter M. Carlson2, Alexander L. Rakhmilevich2, Stephen D. Gillies4, Hans Loibner5, Alan J. Korman6, Paul M. Sondel2, John S. Kuo2, Zachary S. Morris2
|
1University of Wisconsin, Madison, WI, USA 2UW Madison, Madison, WI, USA 3UM Madison, Madison, WI, USA 4UW Madison, Carlisle, MA, USA 5UW Madison, Vienna, Austria 6UW Madison, Redwood City, CA, USA
|
Vaccine | Radiotherapy | Cytokine | Antibody | Checkpoint blockade | Surgery | Immune tolerance
|